Scandion Oncology (SCOL.ST) Stock Analysis & AI Equity Report
Scandion Oncology (SCOL.ST) overview
Scandion Oncology (SCOL.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Scandion Oncology reported revenue of DKK 0m and operating profit of DKK 0m; the year-end share price was 0.07 SEK and market capitalisation was N/A. Scandion Oncology is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Scandion Oncology's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-03-14. Data will be refreshed during report generation.
About Scandion Oncology
Scandion Oncology A/S is a Danish clinical-stage biotechnology company developing medicines designed to overcome cancer drug resistance. Its lead program, SCO-101, has been studied in colorectal and pancreatic cancer, supported by a screening platform and earlier-stage compounds aimed at solid tumors. In March 2025, shareholders approved voluntary liquidation.
Generate the Scandion Oncology report
Scandion Oncology is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Scandion Oncology and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.